383 related articles for article (PubMed ID: 33844617)
1. Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma.
Sharma PK; Chauhan MK
Curr Eye Res; 2021 Nov; 46(11):1703-1716. PubMed ID: 33844617
[No Abstract] [Full Text] [Related]
2. Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study.
Gautam N; Kesavan K
Curr Eye Res; 2021 Dec; 46(12):1844-1852. PubMed ID: 34176380
[No Abstract] [Full Text] [Related]
3. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study.
Emad Eldeeb A; Salah S; Ghorab M
Drug Deliv; 2019 Dec; 26(1):509-521. PubMed ID: 31090464
[TBL] [Abstract][Full Text] [Related]
4. Novel topical ophthalmic formulations for management of glaucoma.
Ibrahim MM; Abd-Elgawad AE; Soliman OA; Jablonski MM
Pharm Res; 2013 Nov; 30(11):2818-31. PubMed ID: 23771565
[TBL] [Abstract][Full Text] [Related]
5. Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane.
Singh KH; Shinde UA
Pharmazie; 2011 Aug; 66(8):594-9. PubMed ID: 21901982
[TBL] [Abstract][Full Text] [Related]
6. Formulation design and optimization of cationic-charged liposomes of brimonidine tartrate for effective ocular drug delivery by design of experiment (DoE) approach.
Soni PK; Saini TR
Drug Dev Ind Pharm; 2021 Nov; 47(11):1847-1866. PubMed ID: 35484943
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Bhagav P; Upadhyay H; Chandran S
AAPS PharmSciTech; 2011 Dec; 12(4):1087-101. PubMed ID: 21879393
[TBL] [Abstract][Full Text] [Related]
8. Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate.
Singh KH; Shinde UA
Curr Drug Deliv; 2010 Jul; 7(3):244-51. PubMed ID: 20497099
[TBL] [Abstract][Full Text] [Related]
9. Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment.
Tripathi S; Yadav KS
Daru; 2024 Jun; 32(1):161-175. PubMed ID: 38158475
[TBL] [Abstract][Full Text] [Related]
10. Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 3
Barse RK; Tagalpallewar AA; Kokare CR; Sharma JP; Sharma PK
Drug Dev Ind Pharm; 2018 May; 44(5):800-807. PubMed ID: 29228819
[TBL] [Abstract][Full Text] [Related]
11. Brinzolamide loaded core-shell nanoparticles for enhanced coronial penetration in the treatment of glaucoma.
Song J; Zhang Z
J Appl Biomater Funct Mater; 2020; 18():2280800020942712. PubMed ID: 33151769
[TBL] [Abstract][Full Text] [Related]
12. A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole.
Ahmed TA; Aljaeid BM
Int J Nanomedicine; 2017; 12():1863-1875. PubMed ID: 28331311
[TBL] [Abstract][Full Text] [Related]
13. Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma.
Ibrahim MM; Abd-Elgawad AH; Soliman OA; Jablonski MM
Transl Vis Sci Technol; 2015 Jun; 4(3):12. PubMed ID: 26175958
[TBL] [Abstract][Full Text] [Related]
14. TPGS modified nanoliposomes as an effective ocular delivery system to treat glaucoma.
Jin Q; Li H; Jin Z; Huang L; Wang F; Zhou Y; Liu Y; Jiang C; Oswald J; Wu J; Song X
Int J Pharm; 2018 Dec; 553(1-2):21-28. PubMed ID: 30316795
[TBL] [Abstract][Full Text] [Related]
15. Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits.
Warsi MH; Anwar M; Garg V; Jain GK; Talegaonkar S; Ahmad FJ; Khar RK
Colloids Surf B Biointerfaces; 2014 Oct; 122():423-431. PubMed ID: 25159319
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery.
Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G
J Drug Target; 2011 Jul; 19(6):409-17. PubMed ID: 20678034
[TBL] [Abstract][Full Text] [Related]
17. Development of thermosensitive hydrogel of Amphotericin-B and Lactoferrin combination-loaded PLGA-PEG-PEI nanoparticles for potential eradication of ocular fungal infections:
Elhabal SF; Ghaffar SA; Hager R; Elzohairy NA; Khalifa MM; Mohie PM; Gad RA; Omar NN; Elkomy MH; Khasawneh MA; Abdelaal N
Int J Pharm X; 2023 Dec; 5():100174. PubMed ID: 36908304
[TBL] [Abstract][Full Text] [Related]
18. Cubogel as potential platform for glaucoma management.
Sayed S; Abdel-Moteleb M; Amin MM; Khowessah OM
Drug Deliv; 2021 Dec; 28(1):293-305. PubMed ID: 33509004
[TBL] [Abstract][Full Text] [Related]
19. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study.
Singh J; Chhabra G; Pathak K
Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522
[TBL] [Abstract][Full Text] [Related]
20. Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles.
Schnichels S; Hurst J; de Vries JW; Ullah S; Frößl K; Gruszka A; Löscher M; Bartz-Schmidt KU; Spitzer MS; Herrmann A
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9445-9456. PubMed ID: 33528240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
